Acknowledgments and Disclosures

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure.
Advertisements

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Effect of Physician Asthma Education on Health Care Utilization of Children at Different Income Levels Randall Brown, Noreen Clark, Niko Kaciroti, Molly.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
05/12/04 Lung Health StudySlide 1 of 6 Lung Health Study Heavy Smokers Experienced a Greater Benefit in the Reduction of the Decline Rate of their Pulmonary.
Afrezza® – inhaled human insulin
Bepotastine Besilate Ophthalmic Solution 1.5% and Degree of Reduced Ocular Itching in a Conjunctival Allergen Challenge Test JI Williams 1, G Torkildsen.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
The short-term, between-session reproducibility of Sniff nasal pressure (SnPnas) in COPD patients; Implications for baseline measurements prior to rehabilitation.
Integrated Trial Results of Bepotastine Besilate Ophthalmic Solution 1.5% on Eyelid Swelling in a Clinical Model of Allergic Conjunctivitis TR McNamara.
SGA 2003-W SS Slide 1 Capacity of Oral SINGULAIR to Prevent Asthma Exacerbations CApacidad de SIngulair ™ Oral en la Prevencion de Exacerbaciones.
Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2012.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Pulmonary Function David Zanghi M.S., MBA, ATC/L, CSCS.
FDA Hearing on Suicide and Antidepressants Presentation by Charles F. Reynolds, III, MD UPMC Professor of Geriatric Psychiatry University of Pittsburgh.
Focus Area 24 Respiratory Diseases Progress Review June 29, 2004.
EXUBERA® (insulin [rDNA origin] powder for inhalation) Endocrinologic and Metabolic Drugs Advisory Committee Meeting September 8, 2005 Dr. Neville Jackson.
INPULSIS® trial design and baseline characteristics
ASSOCIATION BETWEEN ABDOMINAL COMPLAINTS AND NARCOTIC USE AMONG PATIENTS WITH SHORT BOWEL SYNDROME RECEIVING TEDUGLUTIDE Ken Fujioka, 1 Khursheed Jeejeebhoy,
Results Participants: 152 Group program and 189 control participants were ≥9 years old and did not significantly differ by demographics or baseline BMI.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir (RAL) in the Clinic: A New Era for Treatment-Experienced Patients? M. Mugavero 1, H. Lin 1, J.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Association of Cognitive Outcomes and Response Status in Late Life Depression: A 12 Month Longitudinal Study David Bickford B.A., Alana Kivowitz B.A.,
Consequences Of Non-Compliance To Osteoporosis Medication Among Osteoporotic Women Ankita Modi, Ph.D, M.D. 1, Jackson Tang, M.Sc. 2, Shuvayu Sen, Ph.D.
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
High-intensity Treatment & Weight Reduction Goal Achievement with MOVE
W. Hoffstetter, A. Box, H. Mimms, P. Serafini, M. Smith, B. M
Key publication slides
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
Predictors of study retention in drug abuse treatment trials
THE EFFICACY GAP BETWEEN CLINICAL TRIAL AND
Anastasiia Raievska (Veramed)
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Key publication slides
Alcohol, Other Drugs, and Health: Current Evidence
Neal B, et al. Diabetes Care 2015;38:403–411
A Growth Curve Analysis Participant Baseline Characteristics
Filming: 15th of Febuary 2016, London, UK
MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins - Meta Analysis of Clamp data From Three Clinical Studies.
Real World Experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in Idiopathic Pulmonary Fibrosis (IPF). Nazia Chaudhuri*,
Subsequent Healthcare Utilization Associated With Early Physical Therapy for New Episodes of Low Back Pain in Older Adults Deven Karvelas, MD University.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
A post-hoc evaluation of the length of antibiotic therapy from IGNITE4: A phase 3 study of eravacycline and meropenem for complicated intra-abdominal.
Interpretation Normal Spirometry Obstructive pattern
Section 7: Aggressive vs moderate approach to lipid lowering
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Roflumilast negli studi di Fase III: i dati di efficacia
Results Introduction Conclusion Methods THU0514 References
Helen Barraclough, MSc, Ramaswamy Govindan, MD 
The efficacy and safety of omalizumab in pediatric allergic asthma
Identificazione del sottogruppo di pazienti responsivi
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.
Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.
Eckard Hamelmann, MD, Eric D
Roflumilast in aggiunta ai corticosteroidi inalatori
Within-Subject Variability of Insulin Exposure and Metabolic Activity Following Replicate Doses of Technosphere® Insulin Inhalation Powder (TI) in Patients.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
D94- COPD: EPIDEMIOLOGY AND THERAPY
Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.
Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.
A post-hoc evaluation of the length of antibiotic therapy from IGNITE4: A phase 3 study of eravacycline and meropenem for complicated intra-abdominal.
Twice daily regimen N=45 MDI regimen N=28 P Value
Charles E. Johnston, MD Anna McClung BSN, RN Scott Paradise
Presentation transcript:

Acknowledgments and Disclosures Effects of Inhaled Technosphere Insulin (TI) on the Pulmonary Function of Patients with T1D and T2D Joseph D. Brain1, Nikhil Amin2, John Stewart3, Elena Nikonova4, Robert Wise5 1Harvard T.H. Chan School of Public Health, Boston, MA, USA; 2MannKind Corporation, Danbury, CT, USA; 3Sanofi Canada, Laval, QC, Canada; 4Sanofi US, Inc., Bridgewater, NJ, USA; 5Johns Hopkins University School of Medicine, Baltimore, MD, USA TI is a novel inhaled rapid-acting insulin (RAI) approved for use in the US. Management of spirometry may be a barrier to TI use, and there are concerns regarding declines in pulmonary function. This analysis explored spirometry data from clinical trials of TI. Spirometry results were assessed using pooled analyses of 7 TI studies (duration 6-24 months). We included 1,842 patients with T1D (mean age 39 years; 51% male) and 2,281 with T2D (mean age 56 years; 56% male) using TI or comparator (RAI, standard of care, placebo). Baseline mean (SD) forced expiratory volume in 1 second (FEV1) values were 3.49 (0.787) L and 3.01 (0.714) L for patients with T1D and T2D, respectively. FEV1 in both TI and comparator groups declined from baseline to 3 months in patients with T1D (TI = –0.063 L, comparator = –0.019 L; p = 0.1414) and T2D (TI = –0.084 L, comparator = –0.043 L; p = 0.1431) (Figure). After 3 months, the decline in FEV1 at each timepoint was comparable between TI and comparator groups. These reductions were a small percentage of the FEV1 and not influenced by significant outliers. In 2 studies where FEV1 was measured after discontinuation, there was no difference between groups after 1 month. Our data, pooled from 7 clinical trials, demonstrate that TI’s effects on pulmonary function are small and develop during the first 3 months of use. After that, TI and comparator groups demonstrate comparable physiologic declines for up to 24 months. *since submitting the abstract an MMRM model including additional patients and data beyond 12 months were run, which resulted in alterations in the original 3 months change from baseline estimates for FEV1 Abstract Methodology Results Study Selection Patient-level data were pooled from 7 prospective Phase 3 randomized controlled trials with a duration of > 6 months that were conducted in adults with T1D or T2D who initiated TI.1-6,8 All patients who were randomized, treated, and had PFT data at baseline and at least 1 follow-up timepoint were considered eligible for inclusion. For inclusion in this analysis, PFT in these trials had to be conducted according to the 2005 American Thoracic Society/European Respiratory Society test quality recommendations. Endpoints and Statistical Analyses For the purposes of these analyses, patients receiving any intervention other than TI were considered as a comparator group; this included treatment with RAI, premix insulin, standard of care, and placebo. Descriptive statistics were used to describe pulmonary function (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC] and FEV1/FVC ratio) at baseline and at selected timepoints. A mixed-model, repeated-measures (MMRM) analysis with baseline FEV1, height, age, gender, and visit by treatment was used to assess change from baseline for FEV1. Slopes from the MMRM analyses between 3 and 24 months were also compared between groups. Changes in Pulmonary Function The least-square (LS) mean changes in pulmonary function parameters from baseline to 24 months assessed by MMRM analysis are shown in Table 2 and the Figure. These reductions in FEV1 represent a small percentage of the FEV1, and were not influenced by significant outliers. From baseline to 24 months, the distribution of change from baseline FEV1 among patients were comparable in the TI and comparator groups (data not shown). There are small drops in FEV1 between baseline and 3 months and between baseline and 24 months, with greater reductions in the TI groups (Table 2). In the 3 studies of patients with T1D and T2D where FEV1 was measured 4 weeks after discontinuation of TI therapy, pulmonary function increased in the TI group (mean FEV1 [SE] +0.037 [0.007] L) and decreased in the comparator group (−0.017 [0.007] L). The difference between TI and comparators is non-progressive, and from 3 to 24 months, the 2 lines are roughly parallel (Figure). Analyses of the slopes from 3 months to 24 months show a similar reduction in FEV1 with both TI and comparator treatment in patients with both T1D (p = 0.200) and T2D (p = 0.991). Table 2. Change in Pulmonary Function Measures From Baseline Derived by MMRM Analysis T1D Variable 3 Months 24 Months TI LS mean (SE) change Comparator LS mean (SE) change) p Value p value FEV1, L −0.062 (0.010) −0.019 (0.010) 0.024 −0.149 (0.016) −0.087 (0.013) 0.041 FVC, L −0.041 (0.009) −0.021 (0.010) 0.186 −0.113 (0.017) −0.074 (0.014) 0.155 FEV1/FVC ratio −0.372 (3582) 0.091 (0.363) 0.007 −0.899 (0.368) −0.229 (0.370) 0.006 T2D −0.077 (0.006) −0.042 (0.007) 0.066 −0.087 (0.014) −0.083 (0.015) −0.051 (0.016) 0.068 −0.189 (0.017) −0.130 (0.018) 0.057 −0.231 (0.553) 0.095 (0.561) 0.222 −0.721 (0.560) −0.070 (0.566) 0.083 Values derived from a MMRM model adjusted for age, sex, and baseline height and including the treatment group-by-visit-by-diabetic type interaction. SE, standard error. Figure. FEV1 Over 24 Months in People With T1D (A) or T2D (B) Treated With TI or Comparator A B 3.7 6 12 18 24 2.6 2.7 2.8 2.9 3.0 3.1 Treatment Duration (Months) FEV1 (L) 6 12 18 24 Treatment Duration (Months) FEV1 (L) TI Comparator 3.6 3.5 3.4 3.3 3.2 Results Introduction Technosphere® insulin inhalation powder (TI) is a novel inhaled human insulin approved in the US for use as a rapid-acting insulin (RAI) to improve glycemic control in adult patients with diabetes. In people with type 1 or type 2 diabetes (T1D and T2D, respectively), TI has been shown to provide a comparable degree of glycemic control with that achieved using premixed insulin or an RAI in combination with basal insulin.1-4 Small, rapidly developing, non-progressive, and reversible declines in pulmonary function have been seen in people treated with TI;1,3,5,6 these declines have also been observed with other inhaled insulins.7 Concerns regarding changes in pulmonary function have led to a recommendation for pulmonary function testing (PFT) in all patients prior to initiating treatment with TI and at additional intervals during therapy. 759 735 628 194 272 134 100 698 657 580 214 340 206 175 n TI Comparator 1,083 910 951 214 611 493 401 858 808 765 244 617 468 421 n TI Comparator Patients and Baseline Demographics Overall, 4,271 patients using either TI or a comparator were included in this analysis: 1,842 with T1D and 2,429 with T2D. Baseline characteristics are shown in Table 1. Baseline mean (SD) FEV1 values were 3.48 (0.782) L for people with T1D and 2.97 (0.707) L for people with T2D: In patients with T1D, mean (SD) baseline FEV1 values were 3.48 (0.766) for TI and 3.51 (0.810) for comparator. In patients with T2D, mean (SD) baseline FEV1 values were 2.99 (0.688) for TI and 3.01 (0.747) for comparator. Data represent LS means ±SE. MMRM analyses were used; FEV1, age, height, and gender as covariates. DISCUSSION This pooled analysis of 7 studies showed slightly greater declines in pulmonary function (FEV1) in those treated with TI compared with comparator treatments during the first 3 months (approximately 30-40 mL difference). After 3 months, the change in pulmonary function was similar to comparators up to 24 months. FEV1 reductions were small in both TI and comparator groups; they represented a small fraction of pulmonary capacity, and the observed treatment group difference disappeared within 1 month of cessation of TI therapy. References 1. Bode BW, et al. Diabetes Care. 2015;38:2266-73. 6. Raskin P, et al. Diabetes Obes Metab. 2012;14:163-73. 2. Garg SK, et al. Diabetes 2011;60 Suppl 1:A250. 7. Hegewald M, et al. Diabetes Technol Ther. 2007;9 Suppl 1:S93-101. 3. Rosenstock J, et al. Lancet. 2010;375:2244-53. 4. Kapsner P, et al. Diabetologia. 2009;52:S1:S386. 8. Amin N, et al. Diabetologia. 2009;52:S94. 5. Rosenstock J, et al. Diabetes Care. 2015;38:2274-81. Table 1. Baseline Characteristics Characteristic Total (N = 4,271) T1D (n = 1,842) T2D (n = 2,429) Mean age, years (SD) 48 (14) 39 (13) 56 (9) Female, n (%) 1,902 (46.1) 905 (49.1) 997 (43.7) White race, n (%) 3,514 (85.2) 1,698 (92.2) 1,816 (79.6) Therapy, n (%) TI 2,293 (53.7) 1,014 (55.0) 1,279 (52.6) RAI 1,611 (37.7) 828 (45.0) 783 (32.2) Standard of care 219 (5.1) 0 (0.0) 219 (9.1) Placebo 148 (3.5) 148 (6.1) SD, standard deviation. Acknowledgments and Disclosures The study was funded by MannKind and Sanofi US, Inc. The authors received writing/editorial support in the preparation Brain: consultant for MannKind and Sanofi. Amin: employee of MannKind. of this poster provided by Nicola Truss, PhD, of Excerpta Stewart: employee of Sanofi Canada. Medica, funded by Sanofi US, Inc. Nikonova: employee of Artech Information Systems, LLC, under contract with Sanofi . AFREZZA, TECHOSPHERE, and are registered trademarks of MannKind Corporation Wise: consultant for MannKind and Sanofi. Objective To provide clinicians with a more detailed understanding of the timing and extent of pulmonary function changes associated with TI. Poster 937-P American Diabetes Association • 76th Scientific Sessions • June 10-14, 2016 • New Orleans, LA Contact: Joseph Brain • 617.432.1272 • brain@hsph.harvard.edu